• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Landmark Lipid‐Lowering Trials in the Primary Prevention of Cardiovascular Disease
Abstract Although atherosclerotic cardiovascular disease (CVD) is the most common cause of morbidity and mortality in the world, the long disease latency affords ample opportunity for preventive care. Indeed, lifelong exposure to atherogenic apoliprotein B‐containing lipoproteins has consistently been shown to increase the cumulative risk of suffering a CVD event, including myocardial infarction, stroke, and symptomatic peripheral arterial disease. Over the past 25 years, lipid‐lowering therapies have been developed that are proven to not only lower cholesterol, but also to decrease adverse CVD events and CVD mortali...
Source: Clinical Cardiology - May 1, 2013 Category: Cardiology Authors: Jonathan Chrispin, Seth S. Martin, Rani K. Hasan, Parag H. Joshi, C. Michael Minder, John W. McEvoy, Payal Kohli, Amber E. Johnson, Libin Wang, Michael J. Blaha, Roger S. Blumenthal Tags: Review Source Type: research

Impact of Concomitant Coronary Artery Disease on Atherosclerotic Plaques in the Aortic Arch in Patients With Severe Aortic Stenosis
ConclusionsIn patients with severe AS, concomitant CAD is associated with severe atherosclerotic burden in the aortic arch. This observation suggests that AS patients with concomitant CAD are at a higher risk for stroke, and that careful evaluation of complex arch plaques by TEE is needed for the risk stratification of stroke in these patients.
Source: Clinical Cardiology - April 12, 2013 Category: Cardiology Authors: Suwako Fujita, Kenichi Sugioka, Yoshiki Matsumura, Asahiro Ito, Takeshi Hozumi, Takao Hasegawa, Akihisa Hanatani, Takahiko Naruko, Makiko Ueda, Minoru Yoshiyama Tags: Clinical Investigation Source Type: research

Advances in Stroke Prevention in Atrial Fibrillation: Enhanced Risk Stratification Combined With the Newer Oral Anticoagulants
Abstract Patients with atrial fibrillation (AF) have an increased stroke risk compared with those in sinus rhythm, although the absolute risk for individual patients is modulated by the presence of various additional risk factors. Patient selection for oral anticoagulation for stroke prevention is based on risks of stroke and bleeding. Although CHADS2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack) is the most widely used scheme for evaluating stroke risk in patients with AF, several other stroke risk factors are not included; therefore, many patients' strok...
Source: Clinical Cardiology - April 1, 2013 Category: Cardiology Authors: Freek W. A. Verheugt Tags: Review Source Type: research

Risk Factors, Therapeutic Approaches, and In‐Hospital Outcomes in Mexicans With ST‐Elevation Acute Myocardial Infarction: The RENASICA II Multicenter Registry
ConclusionsLargely modifiable risk factors and preventable short‐term complications are responsible for most STEMI cases and outcomes in this Mexican population.
Source: Clinical Cardiology - March 14, 2013 Category: Cardiology Authors: Úrsulo Juárez‐Herrera, Carlos Jerjes‐Sánchez, Tags: Quality and Outcomes Source Type: research

Cost‐Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation—A Real Patient Data Analysis in a Hong Kong Teaching Hospital
ConclusionsThe study favored dabigatran for stroke prophylaxis in patients with nonvalvular AF in Hong Kong under the current hospital's perspective and provided a reference for further comparisons under patient and subsidization perspectives.
Source: Clinical Cardiology - March 14, 2013 Category: Cardiology Authors: Andy M. Chang, Jason C. S. Ho, Bryan P. Yan, Cheuk Man Yu, Yat Yin Lam, Vivian W. Y. Lee Tags: Clinical Investigation Source Type: research

Novel Oral Anticoagulants in Atrial Fibrillation: A Meta‐analysis of Large, Randomized, Controlled Trials vs Warfarin
Conclusions:Novel oral anticoagulants may be superior to warfarin in patients with atrial fibrillation, reducing the composite of stroke or systemic embolism and lowering all‐cause mortality. The benefit is largely due to fewer hemorrhagic strokes.Ernesto Paolasso, MD, is a national lead investigator for a clinical trial sponsored by Daiichi‐Sankyo investigating a novel oral anticoagulant. Robert Giugliano, MD, SM, is a member of the TIMI Study Group, which has received research grant support from Johnson & Johnson and from Daiichi‐Sankyo related to clinical trials of anticoagulants. Dr. Giugliano has received ho...
Source: Clinical Cardiology - January 1, 2013 Category: Cardiology Authors: Ariel Dogliotti, Ernesto Paolasso, Robert P. Giugliano Tags: Review Source Type: research

Pages: 1  2  3  4  5  6  7  8